. 2016 Mar 15;114(6):669–679. doi: 10.1038/bjc.2016.40

Table 1. Parameter estimates for the integrated semimechanistic PK/PD model for vemurafenib and abemaciclib in mice bearing colo-205 or A375 xenograft tumours.

Parameter	Colo-205 xenograft tumours	A375 xenograft tumours (model estimation)	A375 xenograft tumours (external validation)
Biomarker model
I_max	0.907 (1.7)	*	*
IC_{50,Abemaciclib} (ng ml⁻¹)	4.99 (21)	*	*
IC_{50,Vemurafenib} (ng ml⁻¹)	—	16 800 (7.7)	**
k_out,pMEK (h⁻¹)	—	1.76 (31)	**
k_{out,Cyclin D1} (h⁻¹)	—	0.175 (5.9)	**
γ_{Cyclin D1}	—	5 (fixed)	**
k_R (h⁻¹)	0.154 (6.3)	*	*
k_G1S (h⁻¹)	0.631a	0.618a	**
k_SG2 (h⁻¹)	0.0947a	0.445a	**
k_MG1 (h⁻¹)	0.272a	1.98a	**
k_el (h⁻¹)	0.0463 (29)	*	*
γ_pRb	0.458 (16)	*	*
k_{out,Total Rb} (h⁻¹)	0.0524 (38)	*	*
Tumour model
λ₀ (h⁻¹)	—	0.00290 (9.2)	0.00350 (5.4)
λ₁ (mg h⁻¹)	—	5.16 (41)	6.31 (14)
ω₀ (mg)	—	26.6 (19)	114 (2.9)
k_death,pERK (h⁻¹)	—	0.0128 (29)	**
k_{out,modulator} (h⁻¹)	—	0.00191 (64)	**
Scalar	—	0.0000616 (26)	**
k_death,Rb (h⁻¹)	—	0.00990 (41)	**

For all fitted parameters, standard error of the estimate (%) is given within parentheses.

Estimates of interindividual variability and residual error are provided in Supplementary Table 3.

—, Not used in estimation or simulation.

*Simulation performed using parameter estimate obtained from colo-205 xenograft tumour data.

**Simulation performed using parameter estimate obtained from A375 xenograft tumour data.

Calculated from literature baseline values of cell density in the respective cell line.